Evidence map›Paper›PMID 40438304›Full record

ArticleBeilstein journal of organic chemistry2025

Studies on the syntheses of β-carboline alkaloids brevicarine and brevicolline.

Benedek Batizi, Patrik Pollák, András Dancsó, Péter Keglevich, Gyula Simig, Balázs Volk, Mátyás Milen

Abstract read
In one paragraph

Article in Beilstein journal of organic chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Benedek BatiziDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, H-1111 Budapest, Hungary.
Patrik PollákEgis Pharmaceuticals Plc., Directorate of Drug Substance Development, P. O. Box 100, Keresztúri út 30-38, H-1475 Budapest, Hungary.
András DancsóEgis Pharmaceuticals Plc., Directorate of Drug Substance Development, P. O. Box 100, Keresztúri út 30-38, H-1475 Budapest, Hungary.
Péter KeglevichDepartment of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, H-1111 Budapest, Hungary.
Gyula SimigEgis Pharmaceuticals Plc., Directorate of Drug Substance Development, P. O. Box 100, Keresztúri út 30-38, H-1475 Budapest, Hungary.
Balázs VolkEgis Pharmaceuticals Plc., Directorate of Drug Substance Development, P. O. Box 100, Keresztúri út 30-38, H-1475 Budapest, Hungary.ORCID https://orcid.org/0000-0002-2019-1874
Mátyás MilenEgis Pharmaceuticals Plc., Directorate of Drug Substance Development, P. O. Box 100, Keresztúri út 30-38, H-1475 Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new total synthesis of the β-carboline alkaloid brevicarine is disclosed. The synthesis was carried out starting from an aromatic triflate key intermediate, allowing the introduction of various substituents into position 4 of β-carboline by cross-coupling reactions. Thanks to its scalability, this novel approach ensures a broad accessibility to the target compound for potential pharmacological measurements. Using detailed NMR studies, the NMR signals have been assigned for both the base and its dihydrochloride salt for further confirming their structures. A new synthesis of the related alkaloid brevicolline was also attempted from the same intermediate. However, after successful coupling of β-carboline with

Indexed as

alkaloidCarex brevicollis DCcross-coupling reactiontrifluoroethylationβ-carboline

Identifiers

PMID40438304
PMCPMC12117210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.